ScoreWhy is Qingdao Haier Biomedical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 35.57%
- The company has been able to generate a Return on Capital Employed (avg) of 35.57% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 8.21% and Operating profit at -16.14% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 14.04% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 8.21% and Operating profit at -16.14% over the last 5 years
4
Flat results in Jun 26
- CASH AND EQV(HY) Lowest at CNY 3,412.93 MM
- DEBTORS TURNOVER RATIO(HY) Lowest at 4.99 times
5
With ROE of 4.92%, it has a fair valuation with a 1.76 Price to Book Value
- Over the past year, while the stock has generated a return of 4.76%, its profits have fallen by -37.4%
- At the current price, the company has a high dividend yield of 1.3
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Qingdao Haier Biomedical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Industrial Manufacturing should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Industrial Manufacturing)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Qingdao Haier Biomedical Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Qingdao Haier Biomedical Co., Ltd.
6.65%
-0.31
35.16%
China Shanghai Composite
3.23%
0.23
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.21%
EBIT Growth (5y)
-16.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
0.51
Tax Ratio
2.26%
Dividend Payout Ratio
41.25%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.76%
ROE (avg)
14.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
1.76
EV to EBIT
47.75
EV to EBITDA
28.03
EV to Capital Employed
2.06
EV to Sales
2.85
PEG Ratio
NA
Dividend Yield
1.34%
ROCE (Latest)
4.31%
ROE (Latest)
4.92%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 402.93 MM
RAW MATERIAL COST(Y)
Fallen by -10.66% (YoY
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at CNY 3,412.93 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.99 times
Here's what is working for Qingdao Haier Biomedical Co., Ltd.
Operating Cash Flow
Highest at CNY 402.93 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Raw Material Cost
Fallen by -10.66% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Qingdao Haier Biomedical Co., Ltd.
Cash and Eqv
Lowest at CNY 3,412.93 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 4.99 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Footer loading
